RxDoctor Payments Data

Adam Carinci, MD

Interventional Pain Medicine · Baton Rouge, LANPI 1336285790

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (54.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Abbott accounts for 72.8% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $14,546 and has fallen 95.4% since, to $670 in 2025.

$17,479in general payments, 2019–2025

Across 103 payments — averaging $169.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$13K
  • Vertos Medical, Inc.$2K
  • Boston Scientific$701
  • Spinal Simplicity, LLC$693
  • Pacira Pharmaceuticals Incorporated$433
  • SPR Therapeutics, Inc$418
  • plus $959 from 9 others
$74,209in research payments, 2019–2025

Across 19 payments — averaging $3905.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Avanos Medical$74K

What the payments were for

  • Consulting fees$1,2397%
  • Speaking & faculty fees$3,73721%
  • Travel & lodging$9,56455%
  • Food & beverage$2,93917%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,479 in reported general payments places this provider in the 80th percentile of 57 interventional pain medicine providers in Louisiana.

See all interventional pain medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$72,201
Medicare patients
135
Services billed
783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen26$796
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen19$544
Pregabalin33$542
Oxycodone Hcl34$407
Gabapentin27$381
Tizanidine Hcl45$339
Tramadol Hcl20$109
Baclofen17$92

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →